Patents by Inventor Ulrike BAUDER-WÜST

Ulrike BAUDER-WÜST has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190336622
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: July 12, 2019
    Publication date: November 7, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Double-labeled probe for molecular imaging and use thereof
    Patent number: 10406246
    Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: September 10, 2019
    Assignee: Deutsches Kresbsforschungszentrum
    Inventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn
  • Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10398791
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 3, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190060491
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: August 28, 2018
    Publication date: February 28, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190008988
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: July 18, 2018
    Publication date: January 10, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA, Hans-Christian KLIEM, Clemens KRATOCHWIL
  • 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER
    Publication number: 20180194729
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Inventors: Jens CARDINALE, Martin SCHAEFER, Klaus KOPKA, Matthias EDER, Ulrike BAUDER-WUEST, Michael EISENHUT, Martina BENESOVA, Uwe HABERKORN, Frederik L. GIESEL
  • 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10016519
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 10, 2018
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRIUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Klaus Kopka, Martina Benesova, Jens Cardinale, Matthias Eder, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut
  • 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20170246327
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
    Type: Application
    Filed: March 20, 2017
    Publication date: August 31, 2017
    Inventors: Klaus KOPKA, Martina Benesova, Jens Cardinale, Matthias Eder, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe Haberkorn, Michael Eisenhut
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20160228587
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: April 18, 2016
    Publication date: August 11, 2016
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Double-Labeled Probe for Molecular Imaging and Use Thereof
    Publication number: 20150110715
    Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.
    Type: Application
    Filed: July 18, 2014
    Publication date: April 23, 2015
    Applicants: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG, DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn
  • CYLIC POLYAMINES FOR BINDING PHOSPHATIDYLSERINE
    Publication number: 20110177002
    Abstract: The invention pertains to a compound for detecting cell death. According to the invention, the compound comprises a cyclic polyamine unit for the complexation of a bi- or trivalent metal ion. The compound of the invention may contain a reporting tag like fluorescein or a radioisotope including substituent.
    Type: Application
    Filed: July 14, 2009
    Publication date: July 21, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Sabine Zitzmann-Kolbe, Ulrike Bauder-Wuest, Michael Eisenhut, Doerte Oltmanns